• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Pertuzumab lengthens survival in metastatic breast cancer [CLEOPATRA Trial]

byMaren ShapiroandLeah Hawkins Bressler, MD, MPH
February 22, 2015
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adding pertuzumab (Perjeta) to trastuzumab (Herceptin) and chemotherapy increased average overall survival by nearly 16 months in women with HER2-positive metastatic breast cancer.

2. The addition of pertuzumab increased progression-free survival by more than six months.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Breast cancer is the most common cancer in women and kills roughly 40,000 women per year in the United States. The overexpression of human epidermal growth factor receptor 2 (HER2) protein in a breast tumor is associated with a more aggressive cancer and worse prognosis. Fortunately, technological advancements have allowed physicians to develop targeted therapies that are specific to this mutant protein. Trastuzumab, or Herceptin, is an antibody designed to interfere with the HER2 receptor and was first approved in 1998. Pertuzumab, commercially known as Perjeta, is an antibody against a different portion of the HER2 receptor and received FDA approval in 2012. Preclinical data has suggested that combining pertuzumab and trastuzumab results in a stronger signal blockade and greater benefit than either antibody alone. In the CLEOPATRA trial, researchers evaluated this finding in a randomized, double-blind, placebo-controlled, phase 3 trial by adding pertuzumab to trastuzumab and docetaxel (a standard chemotherapy agent) for first-line treatment of women with HER2-positive metastatic breast cancer. Preliminary findings yielded promising results and the present work represents follow-up data at a median of 50 months.

Adding pertuzumab to a regimen of trastuzumab and chemotherapy was associated with a nearly 16 month increase in overall survival. Moreover, women who received pertuzumab experienced a 6 month increase in progression-free survival. Patients in the control group who later crossed over to receive pertuzumab were included in the control group analysis, such that effect estimates may be underestimated. This study evaluated patients with metastatic disease and cannot be applied to women with early-stage disease. Confirmation of the findings using long-term follow-up data would further support the addition of pertuzumab to the chemotherapeutic treatment regimen for metastatic HER2-positive breast cancers.

Click to read the study in NEJM

Relevant Reading: Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

RELATED REPORTS

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Several factors influence health programs conducted in the African American Church

In-Depth [randomized controlled trial]: Women with HER2-positive metastatic breast cancer who had not previously received chemotherapy or anti-HER2 therapy were randomized to receive either a combination of pertuzumab, trastuzumab and docetaxel (n=402) or a placebo, trastuzumab and docetaxel (n=406) as part of the CLEOPATRA trial. Outcomes included overall survival, progression-free survival, duration of response and safety. Participants were followed for a median of 50 months.

Women randomized to pertuzumab had an increased median survival compared to controls (56.5 vs. 40.8 months, p<0.001). Median progression-free survival was 6.3 months longer in the pertuzumab group (18.7 vs. 12.4 months, p<0.001). Adverse events more common in the pertuzumab group were diarrhea, upper respiratory tract infection, pruritus (itching) and muscle spasm.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancer
Previous Post

Mass treatment with azithromycin may be effective in eradicating yaws

Next Post

Improved shoulder dystocia management and outcomes after training

RelatedReports

2 Minute Medicine Rewind March 4, 2019
Chronic Disease

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

June 16, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression
StudyGraphics

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

May 3, 2022
Next Post
Obtaining consent for c-section during labor may be suboptimal

Improved shoulder dystocia management and outcomes after training

Ultrasound-accelerated thrombolysis may improve pulmonary embolism outcomes

Ultrasound-accelerated thrombolysis may improve pulmonary embolism outcomes

Topical pimecrolimus use for atopic dermatitis not linked to malignancy

Topical pimecrolimus use for atopic dermatitis not linked to malignancy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.